WHO WE ARE

Located in the ESPCI incubator in Paris, France, Cardiawave was created at the end of 2014 as a result of a partnership of over 6 years between the team at the Langevin Institute, a world leader in ultrasound imaging and therapy, and the team at the Georges Pompidou European Hospital (HEGP), a leader in the field of valve disease and cardiac ultrasound imaging. This partnership allowed them to develop a revolutionary new noninvasive therapy using focused ultrasounds to treat heart valve disease, particularly calcified aortic stenosis (CAS).

We develop a unique noninvasive, real-time image-guided medical device for heart valve disease treatment using a cutting-edge histotripsy technology with no thermal injury.

Cardiawave has won several awards and contests:

  • 2015 Prize-winner of Worldwide Innovation Contest (CMI), 2nd phase
  • 2015 Prize winner of Fondation pour l’Innovation Thérapeutique Béatrice Denys
  • 2014 Prize-winner of Worldwide Innovation Contest (CMI), 1st phase
  • 2014 Prize-winner of the French National Contest for Innovative Technologies Companies.»